Skip to main content
Atta Behfar, MD, Cardiology, Rochester, MN

Atta Behfar MD

Heart Failure & Transplantation, Interventional Cardiology, Cardiac Critical Care


Russ and Kathy Van Cleve Professor of Regenerative Medicine

Join to View Full Profile
  • 200 1st Street SWRochester, MN 55905

Dr. Behfar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Cardiovascular Disease, 2009 - 2013
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2006 - 2009
  • Mayo Clinic College of Medicine
    Mayo Clinic College of MedicineClass of 2006

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2007 - 2025
  • WI State Medical License
    WI State Medical License 2014 - 2025
  • Advanced Heart Failure and Transplant Cardiology
    American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
  • Cardiovascular Disease
    American Board of Internal Medicine Cardiovascular Disease

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Imaging Vignette Novel Use for Intracardiac Echocardiography: Evaluation of Patients with Continuous Flow Left Ventricular Assist Devices  
    Atta Behfar, Mahwash Kassi, Andrew N Rosenbaum, ScienceDirect
  • Prevention of Myocarditis Using Regenerative Medicine Therapy  
    Leslie T Cooper, Atta Behfar, Journal of Cardiac Failure

Authored Content

  • Prevention of Myocarditis Using Regenerative Medicine TherapyAugust 2018

Press Mentions

  • RION Announces First Patient Enrolled in Phase 1b Clinical Study Evaluating Purified Exosome Product™ (PEP™) for Knee Osteoarthritis
    RION Announces First Patient Enrolled in Phase 1b Clinical Study Evaluating Purified Exosome Product™ (PEP™) for Knee OsteoarthritisMarch 11th, 2025
  • RION Announces Final Patient Enrolled in the Phase 2 Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers
    RION Announces Final Patient Enrolled in the Phase 2 Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot UlcersJanuary 13th, 2025
  • RION Announces Initiation of Phase 1b Clinical Study to Evaluate Purified Exosome Product™ (PEP™) for Knee Osteoarthritis
    RION Announces Initiation of Phase 1b Clinical Study to Evaluate Purified Exosome Product™ (PEP™) for Knee OsteoarthritisSeptember 10th, 2024
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: